A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

Key Inclusion Criteria:

• Male and female participants >= 18 and =< 70 years (at the time of the screeningvisit).

• Diagnosis of systemic sclerosis, as defined by the 2013 American College ofRheumatology/ European League Against Rheumatism (ACR/EULAR) classification criteriafor SSc (van den Hoogen et al 2013) and meet the dcSSc subset classificationaccording to LeRoy (LeRoy 1988)

• Disease duration of =< 60 months (defined as time from the first non-Raynaudphenomenon manifestation, e.g., puffy hands, scleroderma, digital ulcers,arthralgia, dyspnea)

• mRSS units of >= 15 and =< 45 at the time of the screening visit

• Active disease that meets at least one of the following criteria at screening:

• Disease duration of =< 18 months defined as time from the first non-Raynaudphenomenon manifestation

• Increase in mRSS of >= 3 units compared with the most recent assessmentperformed within the previous 6 months

• Involvement of one new body area and an increase in mRSS of >= 2 units comparedwith the most recent assessment performed within the previous 6 months

• Involvement of two new body areas within the previous 6 months

• Elevated acute phase reactants (ESR) >= 30 mm/hr or high-sensitivity C-reactiveprotein (hsCRP) >= 6 mg/dL)

• Presence of interstitial lung disease (ILD) and ATA autoantibody positivity

• Modified EUSTAR disease activity index (mDAI) > 2.5

• Participant must be positive for at least one of the following autoantibodies:

• anti-topoisomerase I (ATA) (also known as anti-SCL-70)

• anti-RNA polymerase III (anti-RNAP3)

• anti-nuclear antibody (ANA) (≥ 1:80) Participants who are positive only for ANA (while being negative for both ATA /anti-RNAP3) will be limited to 30% of theoverall randomized study population.

Key Exclusion Criteria:

• Rheumatic disease other than dcSSc, including limited cutaneous disease (lcSSc) orsine scleroderma at the screening visit. Secondary Sjogren's disease and sclerodermamyopathy are not exclusionary.

• Positive anti-centromere antibody (ACA+) without positive ATA or anti-RNAP3autoantibody result at the screening visit

• Previous improvement (decrease) in mRSS > 10 units

• Pulmonary disease with FVC ≤ 50% of predicted or diffusing capacity of the lung forcarbon monoxide (DLCO, corrected for hemoglobin) ≤ 40% of predicted at the screeningvisit

• WHO Functional Class 3 or higher assessment for pulmonary arterial hypertension (PAH, as defined on right heart catheterization), receiving IV therapy for PAH orevidence of other moderately severe pulmonary disease

• Participants treated with cyclophosphamide within 12 weeks prior to Baseline.

• Prior use of a B-cell depleting therapy other than ianalumab (e.g., rituximab, otheranti-CD20 mAb, anti-CD22 mAb, or anti-CD52 mAb) administered within 36 weeks priorto randomization, or as long as B cell count is less than the lower limit of normalor baseline value prior to receipt of B cell-depleting therapy (whichever is lower)

• Treatment with biologic agents, such as intravenous immunoglobulin or monoclonalantibodies, including marketed drugs, within 12 weeks or 5 half-lives (whichever islonger) prior to baseline visit, unless explicitly allowed in inclusion criteria

• Treatment with any investigational agent within ≤ 4 weeks (or 5 half-lives of theinvestigational drug, whichever is longer) of the baseline visit

• Use of anti-fibrotic agents including colchicine, D-penicillamine, pirfenidone, ortyrosine kinase inhibitors (e.g., nintedanib, nilotinib, imatinib, dasatinib) in the 4 weeks prior to baseline visit.

• Previous treatment with chlorambucil, bone marrow transplantation or total lymphoidirradiation.

Other protocol-defined inclusion/exclusion criteria may apply.